IPH4102; An Anti-KIR3DL2 Monoclonal Antibody in Refractory Sezary Syndrome: Results From a Multicenter Phase 1 Trial

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2019年 / 17卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：10 / 12
页数：3
相关论文
共 50 条
  • [31] Safety and Efficacy of the Anti-alpha Synuclein Monoclonal Antibody Lu AF82422 for the Treatment of Patients with MSA: Results from the Phase 2 AMULET Trial
    Singer, W.
    Zanigni, S.
    Kjaersgaard, L.
    Wiedemann, J.
    Kallunki, P.
    Kompus, K.
    Jorgensen, M.
    Flensburg, M.
    Bidani, A.
    Molinuevo, J. L.
    Takeda, A.
    Gronning, B.
    Luthman, J.
    MOVEMENT DISORDERS, 2024, 39 : S10 - S11
  • [32] Evidence of immunogenicity with the anti-idiotypic monoclonal antibody vaccine 1E1O. Results from a phase I clinical trial in breast cancer patients.
    Castro, MA
    Guthmann, M
    Cinat, G
    Venier, C
    Bitton, R
    Koliren, L
    Alvarez, AM
    Fainbom, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 181S - 181S
  • [33] SECUKINUMAB, A HUMAN ANTI-INTERLEUKIN-17A MONOCLONAL ANTIBODY, SIGNIFICANTLY REDUCES PSORIASIS BURDEN IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 3 RANDOMIZED CONTROLLED TRIAL
    Nash, P.
    Gottlieb, A.
    Mease, P.
    McInnes, I.
    Kirkham, B.
    Kavanaugh, A.
    Rahman, P.
    Pricop, L.
    Yuan, J.
    Richards, H.
    Mpofu, S.
    INTERNAL MEDICINE JOURNAL, 2015, 45 : 42 - 42
  • [34] Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial
    Gottlieb, Alice B.
    Mease, Philip
    McInnes, Iain B.
    Kirkham, Bruce
    Kavanaugh, Arthur
    Rahman, Proton
    Nash, Peter
    Pricop, Luminita
    Yuan, Jiacheng
    Richards, Hanno
    Mpofu, Shephard
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S233 - S233
  • [35] Intralesional Injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRPaFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and Sezary syndrome: Interim results of a multicenter Phase 1 trial
    Querfeld, Christiane
    Thompson, John A.
    Taylor, Matthew
    Pillai, Raju
    Johnson, Lisa D. S.
    Catalano, Tina
    Petrova, Penka S.
    Uger, Bob A.
    Irwin, Meghan
    Thompson, Theresa
    Sievers, Eric L.
    Akilov, Oleg
    EUROPEAN JOURNAL OF CANCER, 2018, 101 : S34 - S34
  • [36] Efficacy Results from the Phase 2b SYNERGY Study: Treatment of Disabling Multiple Sclerosis with the Anti-LINGO-1 Monoclonal Antibody Opicinumab
    Mellion, Michelle
    Edwards, Keith R.
    Hupperts, Raymond
    Drulovic, Jelena
    Montalban, Xavier
    Hartung, Hans-Peter
    Brochet, Bruno
    Calabresi, Peter A.
    Rudick, Richard
    Ibrahim, Adama
    Zhang, Yiwei
    Xu, Lei
    Cadavid, Diego
    NEUROLOGY, 2017, 88
  • [37] The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Lenalidomide in Chinese Patients with Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma: Results of a Multicenter, Single-Arm, Phase 1b/2 Trial
    Shi, Yuankai
    Qin, Yan
    Song, Yongping
    Zhou, Keshu
    Zhou, Hui
    Jing, Hongmei
    Xiang, Ying
    Wang, Zhao
    Wang, Zhen
    Zang, Aimin
    Bai, Ou
    Li, Zhenyu
    Zhang, Huilai
    BLOOD, 2021, 138
  • [38] SAFETY AND EFFICACY RESULTS FROM A PHASE 1/2 STUDY OF THE ANTI-IGF-IR ANTIBODY FIGITUMUMAB IN PATIENTS WITH REFRACTORY EWING'S AND OTHER SARCOMAS
    Juergens, H.
    Daw, N. C.
    Oberlin, O.
    Ferrari, S.
    Villarroel, M.
    Doz, F.
    Whelan, J. S.
    Wang, T.
    Paccagnella, L.
    ANNALS OF ONCOLOGY, 2010, 21 : 408 - 408
  • [39] Phase 1b Trial of Anti-Immunoglobulin-like Transcript 3 Monoclonal Antibody MK-0482 Monotherapy in Relapsed/ Refractory Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia
    Issa, Ghayas C.
    Lavie, David
    Przespolewski, Amanda
    George, Suraj Konnath
    Huang, Mo
    Chen, Mei
    BLOOD, 2022, 140 : 11759 - 11760
  • [40] Y MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial
    Raab, Marc S.
    Engelhardt, Monika
    Blank, Antje
    Goldschmidt, Hartmut
    Agis, Hermine
    Blau, Igor W.
    Einsele, Hermann
    Ferstl, Barbara
    Schub, Natalie
    Roellig, Christoph
    Weisel, Katja
    Winderlich, Mark
    Griese, Janine
    Haertle, Stefan
    Weirather, Johannes
    Jarutat, Tiantom
    Peschel, Christian
    Chatterjee, Manik
    LANCET HAEMATOLOGY, 2020, 7 (05): : E381 - E394
12345